CJC-1295 (no dac) 5mg + Ipamorelin 5mg

Within Europe this product is supplied including bacteriostatic water; outside Europe only the peptide vial is provided. For research use only – not for human or veterinary use.   Product Overview This 5 mg + 5 mg lyophilized research blend combines CJC-1295 no DAC (MOD GRF 1-29) with Ipamorelin to support laboratory-based evaluation of pulsatile GH-axis modulation. Analytical verification confirms identity, assay content and purity for both peptides, enabling controlled biochemical modelling.   Peptide Overview Between 2013 and 2025 research interest in short-acting GH-related peptides increased significantly. The combined evaluation of CJC-1295 no DAC and Ipamorelin allows laboratories to study receptor-specific responses, pituitary signalling behaviour and comparative kinetics under tightly managed in-vitro conditions.   Historical Background and Scientific Context GRF-based peptides such as MOD GRF 1-29 and GHRP-class peptides like Ipamorelin became established research tools across biological studies focusing on GH-axis modulation. This dual-peptide blend offers researchers an opportunity to examine biochemical interactions, signalling patterns and comparative receptor dynamics using two validated short-acting agents.   Mechanistic Focus in Research

• Modelling short-acting GH-axis stimulation
• In-vitro evaluation of pituitary receptor interactions
• Biochemical comparison of GRF and GHRP activity
• Cellular-response profiling under controlled conditions
• Structure-function analysis of GH-modulating peptides

  Analytical Verification (COA) Independent Liquilabs analysis confirms full analytical validation for Batch GF082025021. Key results include:

• Ipamorelin Assay: 4.56 mg
• Ipamorelin RT Identification: 0.989
• Ipamorelin Spectrum Identification: 991
• Ipamorelin Purity: above 99.8 percent
• CJC-1295 no DAC (MOD GRF 1-29) Assay: 5.15 mg
• MOD GRF 1-29 RT Identification: 0.992
• MOD GRF 1-29 Spectrum Identification: 982
• MOD GRF 1-29 Purity: above 99.8 percent
• Endotoxins: below 0.001 EU per mg
• Microbial Growth: not detected for aerobic count, yeast or mold
• Heavy Metals: not detected including arsenic cadmium lead mercury nickel cobalt vanadium

All analytical data originate from validated chromatographic, spectroscopic and microbiological procedures ensuring transparency and traceability.   Research Applications

• Pulsatile GH-axis modelling
• In-vitro receptor behaviour studies
• Comparative GRF and GHRP peptide evaluation
• Biochemical response and kinetic profiling
• Controlled GH-modulation experiments

 

Grail Formula Quality

Every Grail Formula research peptide undergoes independent laboratory testing for purity, identity, structural integrity and microbial safety. All batches are verified for stability, low endotoxin levels and reproducibility to ensure reliable scientific outcomes.

When You Choose Grail Formula…

Researchers receive fully documented peptides with batch-number traceability, sealed-vial integrity and transparent laboratory verification. EU shipments include sterile bacteriostatic water; outside the EU only the peptide vial is supplied.

Used solely for in vitro experiments and cannot be:

• Used in clinical trials involving humans
• Administered to humans as part of an experiment or investigation
• Supplied to another party for human investigational use

• Verified and analysed with Liquilabs s.r.o. Czechia
• Above 99.8 percent purity for both peptides
• No detectable heavy metals or microbial contamination
• Endotoxin below 0.001 EU per mg
• Batch GF082025021 – Published August 2025
• EU shipments include bacteriostatic water
• For research use only – not for human or veterinary use

For laboratory research only. Not intended for human consumption, injection, or cosmetic use.

This product is for research purposes only. Not for human use or diagnostic/therapeutic applications. Keep out of reach of children.